Introduction Of EVO+ Will Open Market Opportunities In 2025

Published
13 Sep 24
Updated
06 Aug 25
AnalystConsensusTarget's Fair Value
US$22.11
23.3% overvalued intrinsic discount
06 Aug
US$27.26
Loading
1Y
-29.3%
7D
47.4%

Author's Valuation

US$22.1

23.3% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on06 Aug 25
Fair value Increased 15%

Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.

Shared on01 May 25
Fair value Increased 19%

Shared on23 Apr 25
Fair value Decreased 0.86%

AnalystConsensusTarget has increased revenue growth from 1.1% to 1.8%.

Shared on17 Apr 25

AnalystConsensusTarget has decreased revenue growth from 1.5% to 1.1%.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Decreased 3.98%

AnalystConsensusTarget has decreased revenue growth from 14.4% to 1.5%, increased profit margin from 9.5% to 13.0% and decreased future PE multiple from 56.9x to 26.1x.